Lv3
370 积分 2020-07-12 加入
Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse Events
1天前
待确认
Hallmarks of liver cancer: Therapeutic implications
2个月前
已完结
Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
5个月前
已完结
Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape
7个月前
已完结
Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
7个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1年前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1年前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
1年前
已完结
皖公网安备34019202002308
